Advertisement

Combination of MEK Inhibitor and the JAK2-STAT3 Pathway Inhibition for the Therapy of Colon Cancer

  • Jianying Jin
  • Qunyi Guo
  • Jingjing Xie
  • Dan Jin
  • Yanan ZhuEmail author
Original Article
  • 31 Downloads

Abstract

The study aimed to investigate the reason of HCT116 cell resistance to MEK inhibitor, and the combination treatment effects of MEK inhibitor AZD6244 and JAK2/STAT3 inhibitor AG490 on colon cancer in vitro and in vivo, including cell viability, apoptosis, and explore the partial mechanisms focused on AZD6244 promoted the activation of JAK2-STAT3 pathways. In vitro, we examined the HCT116 cell viability by CCK8, cell apoptosis by flow cytometry; Western blot measured p-ERK, p-JAK2, p-STAT3 and STAT3 expression. In vivo, nude mice were subcutaneously injected by HCT116 cells. The tumor volume and weight were detected. HCT116 cell resistance to MEK inhibitor AZD6244, which inhibited the activation of ERK and promoted the activation of JAK2-STAT3 signaling. The combination treatment of AZD6244 and AG490 significantly inhibited cell viability and induced cell apoptosis, and completely inhibited the activation of ERK and JAK2-STAT3 signaling. Combination treatment of AZD6244 and AG490 had a stronger effect than that of AZD6244 as a monotherapy in vitro and in vivo. The treatment of AZD6244 on K-Ras mutations HCT116 cells promoted the activation of JAK2/STAT3 signaling. JAK2/STAT3 inhibitor AG490 synergistically increases effects of AZD6244 on colon cancer in vitro and in vivo. Collectively, these results provide a rationale for combining inhibitors of the JAK/STAT pathway and MEK inhibitors to reduce the potential impact of drug resistance.

Keywords

MEK inhibitors Colon cancer JAK2 STAT3 

Notes

Acknowledgements

This work was financially supported by Taizhou Science and Technology Planning Project (2016A33170).

Author’s Contribution

Yanan zhu contributed to the design of the study, served as the study coordinator, and helped to review the manuscript. Jianying Jin designed the study, performed experiments, collected data and wrote the manuscript. Qunyi Guo, Jingjing Xie, Dan Jin helped perform experiments and interpret data. All authors read and approved the final manuscript.

Compliance with Ethical Standards

Conflict of Interest

The authors report no conflict of interest. The authors alone are responsible for the content and writing of this article.

References

  1. 1.
    Zhang W, Tong D, Liu F, Li DW, Li JJ et al (2016) RPS7 inhibits colorectal cancer growth via decreasing HIF-1α-mediated glycolysis. Oncotarget 7:5800–5814 [PubMed: 26735579]Google Scholar
  2. 2.
    Lin J, Webber EM, Senger CA, Holmes RS, Whitlock EP (2011) Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer. Am J Cancer Res 1:650–662 [PubMed: 21779535]Google Scholar
  3. 3.
    Grady WM, Pritchard CC (2014) Molecular alterations and biomarkers in colorectal cancer. Toxicol Pathol 42:124–139 [PubMed: 24178577]CrossRefGoogle Scholar
  4. 4.
    Vaughn CP, ZoBell SD, Furtado LV, Baker CL, Samowitz WS (2011) Frequency of KRAS, BRAF, and NRAS mutations in colorectal Cancer. Gene Chromosome Cancer 50:307–312 [PubMed: 21305640]CrossRefGoogle Scholar
  5. 5.
    Pollock CB, Shirasawa S, Sasazuki T, Kolch W, Dhillon AS (2005) Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res 65:1244–1250 [PubMed: 15735008]CrossRefGoogle Scholar
  6. 6.
    Van Der Hoeven D, Cho KJ, Ma X, Chigurupati S, Parton RG, Hancock JF (2013) Fendiline inhibits K-Ras plasma membrane localization and blocks K-Ras signal transmission. Mol Cell Biol 33:237–251 [PubMed: 23129805]CrossRefGoogle Scholar
  7. 7.
    Surade S, Blundell TL (2012) Structural biology and drug discovery of difficult targets: the limits of ligandability. Chem Biol 19:42–50 [PubMed: 22284353]CrossRefGoogle Scholar
  8. 8.
    Chan DA, Giaccia AJ (2011) Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 10:351–364 [PubMed: 21532565]CrossRefGoogle Scholar
  9. 9.
    Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, Benes CH, Levy DE, Settleman J, Engelman JA, Bardeesy N (2011) STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res 71:5020–5029 [PubMed: 21586612]CrossRefGoogle Scholar
  10. 10.
    Abrams SL, Ruvolo PP, Ruvolo VR, Ligresti G, Martelli AM, Cocco L, Ratti S, Tafuri A, Steelman LS, Candido S, Libra M, McCubrey J (2017) Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. Oncotarget 8(44):76525–76557 [PubMed: 29100331]CrossRefGoogle Scholar
  11. 11.
    Kim DJ, Lee MH, Reddy K, Li Y, Lim DY, Xie H, Lee SY, Yeom YI, Bode AM, Dong Z (2013) CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo. Carcinogenesis 34:1134–1143 [PubMed: 23354306]CrossRefGoogle Scholar
  12. 12.
    Jing J, Greshock J, Holbrook JD, Gilmartin A, Zhang X, McNeil E, Conway T, Moy C, Laquerre S, Bachman K, Wooster R, Degenhardt Y (2012) Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther 11:720–729 [PubMed: 22169769]CrossRefGoogle Scholar
  13. 13.
    Jessen WJ, Miller SJ, Jousma E, Wu JQ, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Hardiman Dudley A, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner N (2013) MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest 123:340–347 [PubMed: 23221341]CrossRefGoogle Scholar
  14. 14.
    Carlino MS, Todd JR, Gowrishankar K, Mijatov B, Pupo GM, Fung C, Snoyman S, Hersey P, Long GV, Kefford RF, Rizos H (2014) Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol Oncol 8:544–554 [PubMed: 24476679]CrossRefGoogle Scholar
  15. 15.
    Chen HJ, Yang ZD, Ding CY, Chu LL, Zhang YY, Terry K, Liu H, Shen Q, Zhou J (2013) Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy. Eur J Med Chem 62:498–507 [PubMed: 23416191]CrossRefGoogle Scholar
  16. 16.
    Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E (2007) Biological characterization of ARRY-142886 (AZD6244), a potent highly selective mitogen-actived protein kinase kinase 1/2 inhibitor. Clin Cancer Res 13:1576–1583 [PubMed: 17332304]CrossRefGoogle Scholar
  17. 17.
    Zhou BY, Der CJ, Cox AD (2016) The role of wild type RAS isoforms in cancer. Semin Cell Dev Biol 58:60–69 [PubMed: 27422332]CrossRefGoogle Scholar
  18. 18.
    Haigis KM, Kendall KR, Wang YF, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T (2008) Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40:600–608 [PubMed: 18372904]CrossRefGoogle Scholar
  19. 19.
    Caunt CJ, Sale MJ, Smith PD, Cook SJ (2015) MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer 15:577–592 [PubMed: 26399658]CrossRefGoogle Scholar
  20. 20.
    Zhao Y, Adjei AA (2014) The clinical development of MEK inhibitors. Nat Rev Clin Oncol 11:385–400 [PubMed: 24840079]CrossRefGoogle Scholar
  21. 21.
    Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, Sandler RS, Kim HJ, Keku TO, der CJ (2009) KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther 8:834–843 [PubMed: 19372556]CrossRefGoogle Scholar
  22. 22.
    Nagaria TS, Shi C, Leduc C, Hoskin V, Sikdar S et al (2017) Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems. Oncotarget 8:80804–80819 [PubMed: 29113345]CrossRefGoogle Scholar
  23. 23.
    Hur EH, Goo BK, Moon J, Choi Y, Hwang JJ, Kim CS, Bae KS, Choi J, Cho SY, Yang SH, Seo J, Lee G, Lee JH (2017) Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells. Oncotarget 8:41387–41400 [PubMed: 28574827]Google Scholar
  24. 24.
    Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W (2009) Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol 220:214–221 [PubMed: 19288493]CrossRefGoogle Scholar
  25. 25.
    Tian F, Yang X, Liu Y, Yuan X, Fan T, Zhang F, Zhao J, Lu J, Jiang Y, Dong Z, Yang Y (2017) Constitutive activated STAT3 is an essential regulator and therapeutic target in esophageal squamous cell carcinoma. Oncotarget 8:88719–88729 [PubMed: 29179470]Google Scholar
  26. 26.
    Mohanty SK, Yagiz K, Pradhan D, Luthringer DJ, Amin MB, Alkan S, Cinar B (2017) STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer. Oncotarget 8:85997–86010 PubMed: 29156772]Google Scholar
  27. 27.
    Holderfield M, Deuker MM, McCormick F, McMahon M (2014) Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 14:455–467. [PubMed: 24957944]CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2019

Authors and Affiliations

  • Jianying Jin
    • 1
  • Qunyi Guo
    • 1
  • Jingjing Xie
    • 1
  • Dan Jin
    • 1
  • Yanan Zhu
    • 2
    Email author
  1. 1.Department of Blood OncologyTaizhou HospitalTaizhouChina
  2. 2.Emergency Center of Taizhou HospitalTaizhouChina

Personalised recommendations